Inspire Index | boehringerone.com

MORE videos

Biomarker Detection in Lung Cancer part2

Biomarker Detection in Lung Cancer: The Pros and Cons of Multiplex Testing - Part2

29^th April, 2020 | Speaker: Herbert Ho-Fung LOONG

Biomarker Detection in Lung Cancer part3

Biomarker Detection in Lung Cancer: The Pros and Cons of Multiplex Testing - Part3

29^th April, 2020 | Speaker: Herbert Ho-Fung LOONG

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part1

26^th August, 2020 | Speaker: Prof. Tetsuya Mitsudomi

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part2

26^th August, 2020 | Speaker: Prof. James Chih-Hsin Yang

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSCLC - Part3

26^th August, 2020 | Speaker: Prof. Tetsuya Mitsudomi & Prof. James Chih-Hsin Yang

Latest advancement in Lung Cancer Clinical Research - Part1

23^rd July, 2020 | Speaker: Prof. Byoung Chul Cho

Latest advancement in Lung Cancer Clinical Research - Part2

23^rd July, 2020 | Speaker: Dr. Ross Soo

Latest advancement in Lung Cancer Clinical Research - Part3

23^rd July, 2020 | Speaker: Prof. Byoung Chul Cho & Dr. Ross Soo

Latest advances in treating advanced NSCLC with driver mutations - Part1

20^th May, 2020 | Speaker: Keunchil Park

Latest advances in treating advanced NSCLC with driver mutations - Part2

20^th May, 2020 | Speaker: Keunchil Park

Latest advances in treating advanced NSCLC with driver mutations - Part3

20^th May, 2020 | Speaker: Keunchil Park

What is Afatinib (Giotrif®)?

Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]

*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Afatinib (Giotrif®)?

The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.

References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.